TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34189135
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion during general anesthesia
Study: 32756643
Drug: Probiotic therapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic therapy (Lactobacillus para casei LPC‐37, Lactobacillus rhamnosus HN001, Lactobacillus acidophilus NCFM, Bifidobacterium lactis HN019, 109 CFU of each strain) for 8 weeks
Study: 32756643
Drug: Placebo (polydextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (polydextrose 1 g day‐1 for 8 weeks)
Study: 36001989
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg BID with aspirin 100 mg
Study: 35830143
Drug: Neutral fluoride
Normalized name: SODIUM FLUORIDE 0.9 mg in 1 g DENTAL AEROSOL, FOAM [KOLORZ NEUTRAL FLUORIDE FOAM TRIPLE MINT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral fluoride gel (NFG)
Study: 36075594
Drug: Scraping needling
Normalized name: Sarapin
DrugBank: Sarracenia Purpurea (DB13965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scraping needling technique combined with western medication
Study: 36075594
Drug: Simple western
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple western medication (control group)
Study: 32020130
Drug: L-PRF application
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF application after surgical removal of impacted third molar
Study: 35018760
Drug: Thiamazole treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamazole treatment for 5-8 months
Study: 35018760
Drug: Thiamazole treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamazole treatment for 9-12 months
Study: 35018760
Drug: Thiamazole treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamazole treatment for more than 12 months
Study: 36314172
Drug: Tegoprazan 25
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 25 mg
Study: 33123304
Drug: Brief acceptance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief acceptance and commitment therapy (individual condition)
Study: 33123304
Drug: Brief acceptance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief acceptance and commitment therapy (group condition)
Study: 34620199
Drug: Time-restricted feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-restricted feeding (10-h restricted feeding treatment program; ad libitum feeding from 8:00 to 18:00 h; fasting between 18:00 and 8:00 h) for 12 weeks
Study: 35078268
Drug: OnabotulinumtoxinA (OBTX‐A)
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA (OBTX‐A) injection
Study: 33651384
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation exercises performed twice a day for 5 days
Study: 35388776
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (ICBT) for 5 weeks
Study: 35388776
Drug: Group-based face-to-face
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based face-to-face cognitive-behavioral therapy (CBT)
Study: 32710787
Drug: 15N-labeled milk
Normalized name: Milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15N-labeled milk protein concentrate (25 g - low protein)
Study: 32710787
Drug: 15N-labeled milk
Normalized name: Milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15N-labeled milk protein concentrate (50 g - high protein)
Study: 33066723
Drug: Ecopipam (25–100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam (25–100 mg/day)
Study: 34836058
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of CMR (3% - 750 mg)
Study: 34836058
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of CMR (2% - 500 mg)
Study: 34836058
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of CMR (1% - 250 mg)
Study: 32139384
Drug: Metformin increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin increased by ≥1,000 mg/day
Study: 32139384
Drug: Metformin unchanged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin unchanged
Study: 32139384
Drug: Metformin decreased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin decreased
Study: 33581721
Drug: ANI-guided group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANI-guided group (loading dose of 75 μg of fentanyl followed by 25 μg when ANI score was under 50)
Study: 33581721
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same loading dose followed by 25 μg every 30 min with additional doses for inadequate analgesia)
Study: 32269181
Drug: 0.066 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.066 mg/kg/day GH
Study: 32269181
Drug: 0.033 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.033 mg/kg/day GH
Study: 34933316
Drug: Povidone-iodine in
Normalized name: povidone-iodine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine in aqueous solution
Study: 32990206
Drug: Combination sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination sedation (propofol with midazolam, fentanyl, dexmedetomidine, and/or ketamine)
Study: 35690060
Drug: e‐cigarettes with
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐cigarettes with 30 mg/g nicotine in e‐liquid
Study: 33872982
Drug: Prolgolimab 1
Normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolgolimab 1 mg/kg every 2 weeks (arm 1)
Study: 33872982
Drug: Prolgolimab 3
Normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolgolimab 3 mg/kg every 3 weeks (arm 2)
Study: 34588237
Drug: Ad26.ZEBOV (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV (first dose)
Study: 34588237
Drug: MVA‐BN‐Filo (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA‐BN‐Filo (second dose)
Study: 34588237
Drug: Ad26.ZEBOV (booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV (booster dose)
Study: 34588237
Drug: Ad26.ZEBOV (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV (first dose) to Ad26.ZEBOV (booster dose)
Study: 36428044
Drug: Solution-focused approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused approach (7-session program of anger management and prevention of violent behavior)
Study: 36380971
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg tablets daily for four weeks
Study: 36380971
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg tablets twice daily for four weeks
Study: 35766956
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg for bolus over 10 min before induction of anesthesia, 1.5 mg/kg/h for continuous infusion)
Study: 35766956
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 µg/kg for bolus over 10 min before induction of anesthesia, 0.4 µg/kg/h for continuous infusion)
Study: 35766956
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus Dexmedetomidine (Lidocaine: 1.5 mg/kg for bolus over 10 min before induction of anesthesia, 1.5 mg/kg/h for continuous infusion; Dexmedetomidine: 0.5 µg/kg for bolus over 10 min before induction of anesthesia, 0.4 µg/kg/h for continuous infusion)
Study: 33833179
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (propofol infusion without vibration analgesia)
Study: 32997437
Drug: Oscillatory positive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillatory positive expiratory pressure therapy (OPEPT)
Study: 35190420
Drug: 'Is insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 'Is insulin right for me?' (intervention)
Study: 32691639
Drug: Dichrostachys glomerata
Normalized name: Dichrostachys cinerea whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichrostachys glomerata (DG; 300 mg/d)
Study: 35704218
Drug: Intravenous calcium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium gluconate (IV) 10% (n = 30)
Study: 35704218
Drug: Oral elemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral elemental calcium (n = 30)
Study: 35704218
Drug: Intravenous calcium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium gluconate (IV) 10%
Study: 35704218
Drug: Oral elemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral elemental calcium
Study: 33455112
Drug: FLOT neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT neoadjuvant chemotherapy with omega 3
Study: 33455112
Drug: FLOT chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT chemotherapy alone
Study: 32453377
Drug: Viltolarsen 40
Normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Viltolarsen 40 mg/kg per week
Study: 32453377
Drug: Viltolarsen 80
Normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Viltolarsen 80 mg/kg per week
Study: 35108294
Drug: Attention-control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-control condition (same dose as intervention but focused on nutrition, physical activity, and weight stigma)
Study: 35529427
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) and Adipose-Derived Mesenchymal Stem Cells (AD-MSCs) injection
Study: 35860417
Drug: Amitriptyline (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (medication group)
Study: 35132039
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment targeting SBP of less than 120 mmHg
Study: 35132039
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment targeting SBP of less than 140 mmHg
Study: 33873028
Drug: Treatment-Control (TCC)
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-Control (TCC)
Study: 34653660
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg in addition to standard therapeutic care)
Study: 34407343
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg atogepant
Study: 34407343
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg atogepant
Study: 34407343
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg atogepant
Study: 33037961
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioural Therapy (GCBT) for 8 weeks
Study: 35094848
Drug: fevipiprant 150
Normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fevipiprant 150 mg
Study: 35094848
Drug: fevipiprant 450
Normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fevipiprant 450 mg
Study: 32297992
Drug: Topiramate 100
Normalized name: topiramate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 100 mg
Study: 32297992
Drug: Topiramate 150
Normalized name: topiramate 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 150 mg
Study: 32006699
Drug: Levorphanol (potent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levorphanol (potent opioid), average final daily dose 132 mg (range 14 to 300 mg), with 5 weeks titration followed by 20 weeks stable dosing.
Study: 34018365
Drug: Hyperin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperin treatment at 75 mg/(kg·d) for 4 weeks
Study: 34018365
Drug: POI model
Approvals — FDA: no, EMA: no, PMDA: no
Description: POI model group (TG at 40 mg/kg twice a day for 2 weeks)
Study: 32714989
Drug: Jaques-Dalcroze Eurhythmics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jaques-Dalcroze Eurhythmics exercise programme (12 weeks, twice a week for 45 minutes)
Study: 33252564
Drug: Ophthalmic Viscosurgical
Normalized name: Viscoat Ophthalmic Viscosurgical Device Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic Viscosurgical Device (OVD)
Study: 33441705
Drug: I3 (100%
Approvals — FDA: no, EMA: no, PMDA: no
Description: I3 (100% of crop's water requirement, non-stress treatment)
Study: 35917364
Drug: Single-dose mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose mebendazole
Study: 35595817
Drug: Sequential paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential paclitaxel treatment followed by fluorinated‐pyrimidine‐based adjuvant chemotherapy
Study: 35595817
Drug: Monotherapy (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (not explicitly named in the abstract)
Study: 35637324
Drug: Prescription-grade Crystalline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription-grade Crystalline Glucosamine Sulfate (pCGS) 1500 mg/day
Study: 34218304
Drug: Rupatadine (RUP)
Normalized name: rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rupatadine (RUP) 10 mg once daily
Study: 34218304
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15–25 mg/week plus placebo
Study: 34234406
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NSAID and steroid eye drops (group A)
Study: 34234406
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NSAID and steroid eye drops (groups A and B)
Study: 32485438
Drug: Citrate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate dose
Study: 32070122
Drug: Group-based music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based music intervention (n=26), delivered twice weekly for 12 weeks
Study: 34048281
Drug: Large dose
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large dose of shoulder strengthening added to usual nonoperative care
Study: 35639159
Drug: l-ERBT
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-ERBT
Study: 32539815
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with c-KIT mutation
Study: 33766992
Drug: IV immunoglobulin
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV immunoglobulin (IVIG) 2 g/kg body weight followed by 3 additional infusions of 1 g/kg at 3-week intervals
Study: 34817561
Drug: Sleep Education
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep Education Therapy (SET)
Study: 34817561
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) with sustained remission of insomnia disorder
Study: 34556520
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU, 48 IU)
Study: 35695687
Drug: Kovir capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kovir capsule
Study: 33407792
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation program (supervised, outpatient, twice weekly for 8 weeks)
Study: 34022445
Drug: Extraperitoneal laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraperitoneal laparoscopic group (X-L)
Study: 34022445
Drug: Transperitoneal laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transperitoneal laparoscopic group (T-L)
Study: 33080934
Drug: 1 cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cup Red Raspberry (RRB) with 8 g Fructo-Oligosaccharides (FOS) per day for 4 weeks
Study: 35916800
Drug: Omega-3 (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (1,000 mg daily for 10 months)
Study: 35916800
Drug: Vitamin-D (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-D (1.5 mL daily for 10 months)
Study: 35916800
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (hydroxyurea + Ibuprofen)
Study: 32679209
Drug: Intralymphatic allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic allergen immunotherapy (ILIT) with 3 injections and a booster 1 year later
Study: 32679209
Drug: Intralymphatic allergen
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic allergen immunotherapy (ILIT)
Study: 35346165
Drug: eGFR <
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR < 60 mL/min/1.73 m²
Study: 36482103
Drug: Atezolizumab plus
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab plus pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide (atezo-chemo)
Study: 36482103
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide (placebo-chemo)
Study: 33694229
Drug: Rectal bacteriotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal bacteriotherapy
Study: 34989174
Drug: NPC-21 1
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-21 1 mg/kg
Study: 34989174
Drug: NPC-21 3
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-21 3 mg/kg
Study: 34989174
Drug: NPC-21 10
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-21 10 mg/kg
Study: 34989174
Drug: NPC-21 20
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-21 20 mg/kg
Study: 34858513
Drug: Ashwagandha SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha SR (300 mg)
Study: 32538005
Drug: Balance acupuncture
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance acupuncture therapy combined with exercise re-learning rehabilitation therapy
Study: 34591105
Drug: AstraZeneca vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AstraZeneca vaccine with information on effectiveness at preventing death from COVID-19
Study: 34591105
Drug: AstraZeneca vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AstraZeneca vaccine with information on overall effectiveness at preventing symptomatic transmission
Study: 34591105
Drug: Johnson &
Normalized name: Johnson & Johnson Eye Sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Johnson & Johnson vaccine with information on effectiveness at preventing death from COVID-19
Study: 34591105
Drug: Johnson &
Normalized name: Johnson & Johnson Eye Sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Johnson & Johnson vaccine with information on overall efficacy at preventing symptomatic infection
Study: 32062728
Drug: Individualized antipsychotic
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized antipsychotic dose reduction
Study: 32062728
Drug: Continuous maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous maintenance treatment
Study: 33403878
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (healthy subjects with RF concentration <11.1 IU/mL)
Study: 32749561
Drug: Association of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Association of mechanical brushing with oral irrigation (WP)
Study: 35859328
Drug: Control (rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rhG-CSF when WBC < 2.0 × 10^9/L or ANC < 1.0 × 10^9/L)
Study: 32651161
Drug: Aldesleukin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldesleukin (both doses)
Study: 32651161
Drug: Aldesleukin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldesleukin (all doses)
Study: 36470777
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation training (including digital operating system training, music therapy, aerobic training, and mental health intervention) for 6 months
Study: 35572853
Drug: LT3 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT3 monotherapy
Study: 32584065
Drug: Randomized planned
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized planned missingness design in daily diary study
Study: 34979943
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PIA)
Study: 32836220
Drug: Aflibercept treatment
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept treatment (1 dose)
Study: 34809573
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 8 mg with bupivacaine 0.25% 40 ml (Group TAPD)
Study: 34809573
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 40 ml (Group TAPA)